Santhera Pharmaceuticals Holding AG’s obtaining a world-wide exclusive license for a product candidate for the treatment of cystic fibrosis from Polyphor

Santhera Pharmaceuticals Holding AG (SIX: SANN) announced that it had obtained a world-wide exclusive license from Swiss pharmaceutical company Polyphor AG to develop and commercialize a…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Paolo Bossi

This content is for Standard 1 Year members only.
Login Join Now